Unraveling the stride: exploring the influence of neurogenic orthostatic hypotension on gait and balance in Parkinson's disease. [PDF]
Imbalzano G +8 more
europepmc +1 more source
Pharmacokinetics and pharmacodynamics of ampreloxetine, a novel, selective norepinephrine reuptake inhibitor, in symptomatic neurogenic orthostatic hypotension. [PDF]
Lo A +4 more
europepmc +1 more source
Atomoxetine on neurogenic orthostatic hypotension: a randomized, double-blind, placebo-controlled crossover trial. [PDF]
Mwesigwa N +9 more
europepmc +1 more source
P.004 Neurogenic orthostatic hypotension results in impaired information processing speed [PDF]
Louise Robinson, Kurt Kimpinski
openalex +1 more source
Norepinephrine Reuptake Inhibition, an Emergent Treatment for Neurogenic Orthostatic Hypotension. [PDF]
Mwesigwa N, Shibao CA.
europepmc +1 more source
Clinical Trials for Neurogenic Orthostatic Hypotension: A Comprehensive Review of Endpoints, Pitfalls, and Challenges. [PDF]
Palma JA, Kaufmann H.
europepmc +1 more source
Longitudinal prevalence of neurogenic orthostatic hypotension in the idiopathic Parkinson Progression Marker Initiative (PPMI) cohort. [PDF]
Beach P, McKay JL.
europepmc +1 more source
Correction to: Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms [PDF]
Sabine Eschlböck +2 more
openalex +1 more source

